Advances in the Use of Biomarkers in Biochip and Microarray Testing: Innovative technologies, growth opportunities and the future market outlook

Introduction

This report gives a strategic insight into the use of biomarkers in biochip and microarray testing. It offers an analysis of the current market landscape and forecast data for the industry going forward, and provides an overview of the key industry players and their areas of expertise.

Scope of this research

• In-depth examination of the various forms of microarrays and biochips.


• Overview of the main industry players and their fields of expertise.


• Analysis of the current market landscape.


• Forecasts for future growth within the industry.

Research and analysis highlights

At present, the leading microarray players are Affymetrix, Agilent, Illumina, and Roche/NimbleGen. Apart from a small number of "heavy hitters", this market is very fragmented.

Many microarray players are preparing to move into diagnostics, either by cultivating multiple diagnostics industry partners (such as Affymetrix) or by forming diagnostics divisions (such as Illumina).

Nucleic acid-based molecular diagnostics, currently worth $3 billion, offers many more opportunities than the existing heavily research-oriented microarray market. The latter market grew very strongly between 1997 and 2003, but is now firmly entrenched in a phase of more modest growth.

Key reasons to purchase this research

• Gain an insight into the R&D history of microarrays and biochips.


• Understand the various forms of microarrays and their uses.


• Identify who the industry's key players are.


• Uncover what lies in store for the microarray market in the future.

For more information please click here